![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | A61K 45/06 | (2006.01) |
C07K 16/18 | (2013.01) | ||
C07K 16/28 | (2006.01) | ||
C07K 16/2896 | (2013.01) | ||
C07K 16/18 | (2006.01) | ||
A61K2039/505 | (2013.01) | ||
C12N 9/24 | (2006.01) | ||
C07K2317/734 | (2013.01) | ||
A61K 35/00 | (2006.01) | ||
A61K 45/06 | (2013.01) | ||
A61P 35/02 | (2006.01) | ||
C07K2317/24 | (2013.01) | ||
A61P 31/12 | (2006.01) | ||
C07K2317/41 | (2013.01) | ||
C12N 9/24 | (2013.01) | ||
C12Y 302/01 | (2013.01) | ||
C12Y 302/01051 | (2013.01) | ||
A61P 1/04 | (2018.01) | ||
A61P 13/12 | (2018.01) | ||
A61P 17/06 | (2018.01) | ||
A61P 19/02 | (2018.01) | ||
A61P 21/04 | (2018.01) | ||
A61P 25/00 | (2018.01) | ||
A61P 27/02 | (2018.01) | ||
A61P 29/00 | (2018.01) | ||
A61P 31/12 | (2018.01) | ||
A61P 31/14 | (2018.01) | ||
A61P 31/18 | (2018.01) | ||
A61P 31/20 | (2018.01) | ||
A61P 31/22 | (2018.01) | ||
A61P 35/00 | (2018.01) | ||
A61P 35/02 | (2018.01) | ||
A61P 37/02 | (2018.01) | ||
A61P 7/00 | (2018.01) | ||
A61P 3/10 | (2018.01) | ||
Y02A 50/30 | (2018.01) |
(11) | Patento numeris | 3149045 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 15799981.4 |
Europos patento paraiškos padavimo data | 2015-05-27 | |
(97) | Europos patento paraiškos paskelbimo data | 2017-04-05 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2023-01-18 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/US2015/032745 |
Data | 2015-05-27 |
(87) | Numeris | WO 2015/184009 |
Data | 2015-12-03 |
(30) | Numeris | Data | Šalis |
201462003136 P | 2014-05-27 | US | |
201462003104 P | 2014-05-27 | US | |
201462003908 P | 2014-05-28 | US | |
201462020199 P | 2014-07-02 | US | |
201562110338 P | 2015-01-30 | US |
(72) |
WONG, Chi-Huey , US
WU, Chung-Yi , CN
MA, Che , CN
|
(73) |
Academia Sinica ,
128, Academia Road, Section 2
Nankang, Taipei 11529,
TW
|
(54) | COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY |
COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY |